Abstract
Chronic loss of sleep damages health and disturbs quality of life. The long-lasting sleep deprivation (SD) as well as sleep abnormalities is a substantial risk factor for major depressive disorder (MDD), although the underlying mechanisms are not clear. In our previous studies, we report the activation of nucleotide-binding domain and leucine-rich repeat protein-3 (NLRP3) inflammasome induced by long-term SD is P2X7 receptors (P2X7R) dependent, and antidepressant fluoxetine could alleviate this neuroinflammasome via 5-HT2B receptors (5-HT2BR) in astrocytes. Here, we discovered that the chronic SD activates astroglial P2X7 receptors, which in turn selectively down-regulated expression of 5-HT2BR in astrocytes. Stimulation of P2X7R induced by SD suppressed the phosphorylation of AKT and FoxO3a selectively in astrocytes, but not in neurones. The over-expression of FoxO3a in astrocytes inhibited expression of 5-HT2BR. Down-regulation of 5-HT2BR instigated by SD suppressed activation of STAT3 and relieved the inhibition of Ca2+-dependent phospholipase A2 (cPLA2). This latter cascade promoted the release of arachidonic acid (AA) and prostaglandin E2 (PGE2). The depressive-like behaviours induced by SD were alleviated in P2X7R-KO mice. Our study reveals the mechanism underlying chronic SD-induced depressive-like behaviors and highlights that blocking P2X7 receptors or activating 5-HT2BR in astrocytes could play a key role for exploring the therapeutic strategies aimed at the depression evoked by sleep disorders.
Main Points Chronic SD selectively down-regulates expression of 5-HT2BR through activation of P2X7R in astrocytes. SD promotes the release of AA and PGE2 via the decreased 5-HT2BR, these factors induce depressive-like behaviors.
Abbreviations
- SD
- sleep deprivation;
- MDD
- major depressive disorder;
- NLRP3
- nucleotide-binding domain and leucine-rich repeat protein-3;
- P2X7R
- P2X7 receptors;
- 5-HT2BR
- 5-HT2B receptors;
- FoxO3a
- Forkhead box O3a;
- cPLA2
- Ca2+-dependent phospholipase A2;
- AA
- arachidonic acid;
- PGE2
- prostaglandin E2;
- ATP
- adenosine-tri-phosphate;
- SSRIs
- serotonin-specific re-uptake inhibitors;
- 5-HT
- 5-hydroxytryptamine;
- EGFR
- epidermal growth factor receptor;
- TCA
- trichloroacetic acid;
- DMEM
- Dulbecco’s modified Eagle’s medium;
- dBcAMP
- dibutyryl cyclic AMP;
- PFA
- paraformaldehyde;
- GAPDH
- glyceraldehyde 3-phosphate dehydrogenase;
- GFP
- green fluorescent protein;
- TST
- Tail suspension test;
- FST
- Forced swimming test;
- COX
- cyclooxygenase;
- WT
- wild type